SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

The human kidney is a masterclass in biological engineering. Responsible for filtering approximately 50 gallons of blood ...

Avoid these 7 low-carb diet mistakes for better health with type 2 diabetes. Plus, learn tips for staying hydrated, eating ...

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

The field of cardiometabolic health has garnered substantial attention due to the increasing prevalence of type 2 diabetes ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

The discovery that diabetes medication could potentially manage hydrocephalus occurred after Dr Magill observed significant ...

A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.